Kovitz Investment Group Partners LLC Has $3.17 Million Stock Position in Iqvia Holdings Inc (NYSE:IQV)

Kovitz Investment Group Partners LLC decreased its stake in Iqvia Holdings Inc (NYSE:IQV) by 5.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,675 shares of the medical research company’s stock after selling 1,220 shares during the period. Kovitz Investment Group Partners LLC’s holdings in Iqvia were worth $3,166,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Piedmont Investment Advisors Inc. boosted its holdings in shares of Iqvia by 8.4% in the first quarter. Piedmont Investment Advisors Inc. now owns 2,555 shares of the medical research company’s stock valued at $368,000 after acquiring an additional 198 shares in the last quarter. Signaturefd LLC boosted its holdings in shares of Iqvia by 147.4% in the first quarter. Signaturefd LLC now owns 705 shares of the medical research company’s stock valued at $101,000 after acquiring an additional 420 shares in the last quarter. Advisor Group Inc. boosted its holdings in shares of Iqvia by 11.9% in the first quarter. Advisor Group Inc. now owns 27,465 shares of the medical research company’s stock valued at $3,950,000 after acquiring an additional 2,918 shares in the last quarter. CIBC World Markets Inc. boosted its holdings in shares of Iqvia by 12.5% in the first quarter. CIBC World Markets Inc. now owns 14,360 shares of the medical research company’s stock valued at $2,066,000 after acquiring an additional 1,601 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. boosted its holdings in shares of Iqvia by 3.2% in the first quarter. Nomura Asset Management Co. Ltd. now owns 26,960 shares of the medical research company’s stock valued at $3,878,000 after acquiring an additional 844 shares in the last quarter. Institutional investors and hedge funds own 89.67% of the company’s stock.

Shares of NYSE IQV traded up $1.06 during midday trading on Monday, hitting $149.31. The company had a trading volume of 354,078 shares, compared to its average volume of 1,595,758. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 1.72. Iqvia Holdings Inc has a twelve month low of $104.90 and a twelve month high of $164.13. The business has a 50-day simple moving average of $154.02 and a two-hundred day simple moving average of $147.41. The firm has a market capitalization of $29.74 billion, a price-to-earnings ratio of 29.16, a price-to-earnings-growth ratio of 1.68 and a beta of 0.90.

Iqvia (NYSE:IQV) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $1.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.38 by $0.01. Iqvia had a net margin of 2.31% and a return on equity of 15.95%. The firm had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.70 billion. During the same quarter last year, the business earned $1.29 earnings per share. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, equities analysts forecast that Iqvia Holdings Inc will post 5.88 EPS for the current year.

Several analysts have recently weighed in on the stock. Barclays set a $180.00 target price on shares of Iqvia and gave the company a “buy” rating in a report on Monday, July 15th. JPMorgan Chase & Co. lifted their target price on shares of Iqvia from $160.00 to $180.00 and gave the company an “overweight” rating in a report on Thursday, July 25th. Credit Suisse Group lifted their target price on shares of Iqvia from $165.00 to $170.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. William Blair reaffirmed an “outperform” rating on shares of Iqvia in a report on Wednesday, June 19th. Finally, Stifel Nicolaus lifted their target price on shares of Iqvia from $167.00 to $178.00 and gave the company a “buy” rating in a report on Wednesday, June 19th. Three equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $162.08.

In related news, insider Kevin C. Knightly sold 4,278 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $158.50, for a total value of $678,063.00. Following the completion of the sale, the insider now owns 4,084 shares in the company, valued at $647,314. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin C. Knightly sold 6,945 shares of the firm’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $158.53, for a total transaction of $1,100,990.85. The disclosure for this sale can be found here. Insiders sold 2,627,251 shares of company stock valued at $412,103,046 in the last quarter. Company insiders own 6.00% of the company’s stock.

Iqvia Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More: What is the Consumer Price Index (CPI)?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.